Anti-VEGF use for ROP is expanding beyond bevacizumab and ranibizumab, with aflibercept’s fusion-protein structure conferring ...
US News evaluated freestanding ASCs only, excluding hospital-affiliated outpatient departments to avoid overlap with hospital ...
An FDA complete response letter for idebenone in LHON indicates unresolved NDA deficiencies and necessitates additional data ...
Aldeyra plans to request a Type A meeting and currently does not intend further clinical trials, asserting rapid-onset ...
NovaBridge Biosciences and Visara have announced topline results from their phase 2a study of VIS-101 for retinal vascular ...
Management prioritizes 5%–10% weight loss and acetazolamide titration guided by Frisén grading, OCT, and visual fields; ...
Tattoo-associated uveitis was once considered rare; however, that appears to be no longer true, according to a new Australian ...
Following a second injection at eight weeks, the patient maintained stable vision and remained dry at 12 weeks, allowing for ...
The 51 st annual American Association for Pediatric Ophthalmology and Strabismus (AAPOS) meeting will convene from March 18 ...
Cross-sectional analysis of the prospective Low Vision Rehabilitation Outcomes Study included 28 US centers and assessed ...
Joseph Anaya, MD, and Ashkan Abbey, MD, discuss the financial barriers facing patients with geographic atrophy, including ...
MFDS IND approval enables a multicenter, randomized, double-blind, vehicle-controlled phase 2 study in ~150 DED patients, randomized 1:1:1 to two dosing arms versus control over 12 weeks. Prior phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results